Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
NCT05431595
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, randomized clinical trial aims to provide evidence on various therapeutic options for palliating delirium, thereby reducing delirium-related distress and ultimately alleviating suffering.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Delirium
- Epileptics
- Neuroleptics
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2/3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- M.D. Anderson Cancer Center
- Last updated on ClinicalTrials.gov
- November 18, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.